drugset / Trial / NCT07085767
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
RandomizedParallel-groupTriple-blindTreatment
Summary
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Timeline
- Start
- 2025-11-03
- Primary completion
- 2028-12
- Completion
- 2032-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Letrozole | Other / unclassified | 2.5 mg | — |
| Subject | Palazestrant | Small molecule | 90 mg | — |
| Background | Ribociclib | Small molecule | 600 mg | — |